An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

“Treatment-resistant depression can be very complicated ... symptom improvement,” the statement quoted Bill Martin of Johnson & Johnson and saying. “With Spravato now approved as a stand ...

Ratings for Johnson & Johnson (NYSE:JNJ) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ...

"Treatment-resistant depression can be very complicated ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

"Treatment-resistant depression can be very complicated ... Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine, said in a statement. "Spravato is now available as ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression. The drug made by Johnson & Johnson under the brand name Spravato passed final ...

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...

Johnson & Johnson said that because there are risks of "serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, and misuse," the drug will only be available ...

Innovation remains core, seen in new products such as SPRAVATO for depression and the OTTAVA robotic system. Johnson & Johnson recently concentrated on fostering innovations within its segments ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant depression. This landmark decision ...